Geron Corp. (GERN) Sees Unusually-High Trading Volume
Geron Corp. (NASDAQ:GERN) shares saw an uptick in trading volume on Monday . 1,357,481 shares changed hands during mid-day trading, an increase of 17% from the previous session’s volume of 1,163,721 shares.The stock last traded at $2.85 and had previously closed at $2.74.
A number of brokerages have weighed in on GERN. FBR & Co reiterated a “buy” rating on shares of Geron Corp. in a report on Sunday, May 8th. Zacks Investment Research lowered shares of Geron Corp. from a “buy” rating to a “hold” rating in a report on Monday, April 25th. One analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $6.20.
The firm’s 50-day moving average is $2.68 and its 200-day moving average is $2.82. The firm has a market cap of $456.73 million and a price-to-earnings ratio of 358.75.
Geron Corp. (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. The firm’s revenue was down 15.9% compared to the same quarter last year. Equities research analysts forecast that Geron Corp. will post ($0.23) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Geron Corp. stock. Morgan Stanley boosted its position in shares of Geron Corp. (NASDAQ:GERN) by 194.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 268,626 shares of the biopharmaceutical company’s stock after buying an additional 177,313 shares during the period. Morgan Stanley owned about 0.17% of Geron Corp. worth $1,300,000 at the end of the most recent reporting period.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.